Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lurbinectedin + paclitaxel
- Development stage
- Unknown
- Lead developer
- PharmaMar
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy of lurbinectedin and paclitaxel that has shown synergism in preclinical studies. This regimen is administered as paclitaxel 80 mg/m² on Days 1 and 8, plus lurbinectedin 2.2 mg/m² on Day 1 of a 21-day cycle. The combination has demonstrated promising efficacy in various advanced solid tumors, particularly in breast cancer, small cell lung cancer, epithelial ovarian cancer, and endometrial cancer.
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on lurbinectedin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lurbinectedin + paclitaxel.